Anti-Myxovirus Resistance Protein-1 Immunoglobulin A Autoantibody in Idiopathic Pulmonary Fibrosis

Table 4

Correlation between titer of anti-MX1 autoantibodies and severity markers of IPF.

Parameters	Anti-MX1 IgG autoantibody	Anti-MX1 IgA autoantibody	Anti-MX1 IgM autoantibody
Anti-MX1 IgG antibody	1	0.585 (<0.001)	0.230 (0.054)
Anti-MX1 IgA antibody	0.585 (<0.001)	1	0.402 (0.001)
Anti-MX1 IgM antibody	0.230 (0.054)	0.402 (0.001)	1
%FVC	−0.209 (0.082)	−0.077 (0.526)	−0.072 (0.556)
%DLco	−0.290 (0.016)	−0.144 (0.239)	−0.115 (0.346)
KL-6	0.211 (0.079)	0.087 (0.475)	0.138 (0.255)
SP-D	0.183 (0.132)	0.094 (0.440)	0.224 (0.064)
Neutrophils in BAL, %	0.263 (0.028)	0.135 (0.266)	0.051 (0.677)
Lymphocytes in BAL, %	−0.060 (0.619)	−0.295 (0.013)	−0.158 (0.191)
HRCT pattern, UIP/possible/inconsistent	0.017 (0.887)	0.023 (0.857)	0.109 (0.307)
GAP stage	0.319 (0.008)	0.272 (0.024)	0.085 (0.489)
mMRC	0.170 (0.157)	0.120 (0.320)	0.058 (0.631)

MX1, myxovirus resistance protein-1; IPF, idiopathic pulmonary fibrosis; FVC, forced vital capacity; DLco, diffusing capacity of carbon monoxide; KL-6, Krebs von den Lungen-6; SP-D, surfactant protein-D; BAL, bronchoalveolar lavage; HRCT, high-resolution computed tomography; UIP, usual interstitial pneumonia; GAP stage, gender, age, and physiology stage; mMRC, modified Medical Research Council score for shortness of breath; Ig, immunoglobulin. Spearman rank correlation was performed, and Rho ( value) was shown in each column.